ASIT Biotech S.A. (ASIT.BR)
0.229 €
0.00 (0.00%)
Rating:
Recommendation:
-
| Symbol | ASIT.BR |
|---|---|
| Price | 0.229 € |
| Beta | 1.331 |
| Volume Avg. | 0.05M |
| Market Cap | - |
| Shares () | - |
| 52 Week Range | 0.229-0.235 |
| 1y Target Est | - |
| DCF Unlevered | ASIT.BR DCF -> | |
|---|---|---|
| DCF Levered | ASIT.BR LDCF -> | |
| ROE | 38.01% | Strong Buy |
| ROA | -36.30% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -93.91% | |
| P/E | -32.71 | Strong Sell |
| P/B | -0.89 |
About
Download (Excel)ASIT Biotech S.A., a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium and internationally. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen rhinitis. The company is also developing hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy. ASIT Biotech S.A. was incorporated in 1997 and is based in Liege, Belgium.